Adlai Nortye Biopharma
Justin Lucas has worked in the field of translational research since 2010. Their career began at Pfizer, where they worked as a Scientist from 2010 to 2018. Justin then moved to Bristol Myers Squibb, where they held the role of Principle Clinical Biomarker Scientist from 2019 to 2020, and Senior Research Investigator from 2018 to 2019. In 2020, they joined The Janssen Pharmaceutical Companies of Johnson & Johnson as Principal Scientist: Oncology Translational Research Lead. Most recently, they were appointed Head of Translational Research at Adlai Nortye USA Inc. in 2022.
Justin Lucas completed a Bachelor of Science (BS) in Biology/Biological Sciences, General from Lafayette College in 2010. Justin then went on to obtain a Master of Science (MS) in Pathology/Experimental Pathology from New York Medical College in 2013. Finally, they earned a Doctor of Philosophy (PhD) in Biochemistry and Molecular Biology from New York Medical College in 2018.
This person is not in any teams
This person is not in any offices
Adlai Nortye Biopharma
1 followers
Adlai Nortye Biopharma is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with our R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, they have built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. They have assembled a world-class management team, built a unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation.